A Study of LY3200882 in Participants With Solid Tumors

Phase 1 Active not recruiting 223 enrolled Eli Lilly and Company

Non-randomizedParallel-groupOpen-labelTreatment

The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors.

Evaluation	Drug	Modality	Dose	Route
Subject	LY3200882	Small molecule	35 mg	Oral
Subject	LY3200882	Small molecule	50 mg	Oral
Background	Cisplatin	Other / unclassified	—	Intravenous
Background	Gemcitabine	Small molecule	—	Intravenous
Background	LODAPOLIMAB	Monoclonal antibody	—	Intravenous
Background	Paclitaxel	Small molecule	—	Intravenous